These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 11370412)
21. Do risk factors for lactic acidosis influence dosing of metformin? Millican S; Cottrell N; Green B J Clin Pharm Ther; 2004 Oct; 29(5):449-54. PubMed ID: 15482389 [TBL] [Abstract][Full Text] [Related]
22. Metformin-induced encephalopathy without lactic acidosis in a patient with contraindication for metformin. Jung EY; Cho HS; Seo JW; Kim DW; Kim HJ; Chang SH; Park DJ Hemodial Int; 2009 Apr; 13(2):172-5. PubMed ID: 19432690 [TBL] [Abstract][Full Text] [Related]
24. [Four cases of lactic acidosis following metformin treatment]. Frid A; Sterner G Lakartidningen; 2006 Sep 6-12; 103(36):2560-2. PubMed ID: 17007201 [No Abstract] [Full Text] [Related]
25. [Metformin--sensible or nonsensible change of treatment in the post-operative phase]. Jost U; Böhrer H Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Aug; 37(8):461-2. PubMed ID: 12165914 [No Abstract] [Full Text] [Related]
26. [DIGAMI 2: breaking the spell of insulin for heart infarct. Re the article in DMW 45/2004]. Martin J Dtsch Med Wochenschr; 2005 Jan; 130(4):175; author reply 175. PubMed ID: 15714684 [No Abstract] [Full Text] [Related]
30. [Metformin. Mode of action and effect of monotherapy and combination therapy on glucose metabolism in type 2 diabetes]. Christiansen AL; Madsbad S Ugeskr Laeger; 2002 Apr; 164(15):2025-8. PubMed ID: 11985000 [TBL] [Abstract][Full Text] [Related]
34. [Metformin in serum. Results of a study as basis for preliminary therapeutic recommendations]. Frid A; Sterner G; Löndahl M; Vinge E; Cato A; Andersson A Lakartidningen; 2009 Feb 11-17; 106(7):428-9. PubMed ID: 19350768 [No Abstract] [Full Text] [Related]
35. Sitagliptin/metformin (Janumet) for type 2 diabetes. Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377 [No Abstract] [Full Text] [Related]
36. Patients with Type 2 diabetes treated with metformin: prevalence of contraindications and their correlation with discontinuation. Rakovac I; Jeitler K; Gfrerer RJ; Habacher W; Seereiner S; Mrak P; Pieber TR; Diabet Med; 2005 May; 22(5):662-4. PubMed ID: 15842528 [No Abstract] [Full Text] [Related]
37. Drugs and intravenous contrast media. Thompson NW; Thompson TJ; Love MH; Young MR BJU Int; 2000 Feb; 85(3):219-21. PubMed ID: 10671870 [No Abstract] [Full Text] [Related]
40. [Prevention of contrast nephropathy; guidelines from the Department Nephrology of the University Medical Centre Groningen]. Hemmelder MH; Hoogendoorn M; Halma C Ned Tijdschr Geneeskd; 2006 Feb; 150(5):275; author reply 275-6. PubMed ID: 16493997 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]